• 繁

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Demant (CPSE:DEMANT) Launches A New Hearing Aid, Is The Stock Fully Priced?

    Simply Wall St·07/27/2026 19:24:07
    語音播報

    Demant (CPSE:DEMANT) has launched a new cosmetic hearing aid that aims to strengthen its position in hearing healthcare at a time when competition from Sonova is intensifying in the largest hearing aid category.

    See our latest analysis for Demant.

    Against this product launch backdrop, Demant's share price has gained 39.2% over the past 90 days and 30.46% year to date to DKK278.4. Longer term total shareholder returns have been modest, including a 3% return over three years and a 28.06% decline over five years.

    If this kind of product driven story interests you, it may be worth widening your search using a screener focused on 129 healthcare AI stocks

    After a 39.2% move in 90 days and modest longer term returns, the question around Demant now is simple: does the current price already reflect the cosmetic hearing aid story, or does the valuation still leave meaningful upside?

    Most Popular Narrative: 11% Overvalued

    Demant's most followed valuation narrative places fair value at DKK251.11, which sits below the current DKK278.4 share price and frames the recent rally in a more cautious light.

    Current market uncertainty and consumer hesitancy, especially among first-time users, are leading to postponed purchases and upgrades, suppressing near-term revenue growth. As global economic conditions and consumer confidence normalize, underlying demographic demand from an aging population is expected to return, providing a tailwind for top-line growth and recurring revenue recovery.

    Read the complete narrative. Read the complete narrative.

    Want to understand why this fair value still leans on higher future earnings and richer margins, even with today’s softer profitability and mixed geographic mix assumptions? See our AI narrative and valuation for Demant.

    Analysts behind this narrative build their case on a specific path for revenue, earnings and P/E multiples, and apply a 6.44% discount rate to bring those future numbers back to today. The result is a fair value that sits between cautious views on current margin pressure and more optimistic expectations that hearing healthcare demand and profitability normalize over time.

    Result: Fair Value of DKK251.11 (OVERVALUED)

    Have a read of the narrative in full and understand what's behind the forecasts.

    However, this Demant narrative could be tested if weaker hearing aid demand persists for longer than analysts expect, or if competition further compresses pricing and margins.

    Find out about the key risks to this Demant narrative.

    Another View: SWS DCF Model Points To Deep Undervaluation

    While the consensus narrative tags Demant as 11% overvalued at DKK278.4, the Simply Wall St DCF model lands in a very different place. On those cash flow assumptions, Demant screens as trading about 46.4% below an estimated fair value of DKK519.16.

    That gap is wide enough to raise a genuine question for investors: are analysts being too cautious on long term cash generation, or is the DCF model too generous on margins and growth?

    To understand how the implied cash flows stack up against your own expectations, it is worth unpacking the mechanics behind this result in more detail, rather than relying on headline labels of cheap or expensive. Look into how the SWS DCF model arrives at its fair value.

    DEMANT Discounted Cash Flow as at Jul 2026
    DEMANT Discounted Cash Flow as at Jul 2026

    Next Steps

    With Demant attracting both optimism and caution in this article, now is a good time to look through the underlying data yourself and stress test the assumptions on risks and rewards. To see a concise summary that highlights both sides of the story, review the 3 key rewards and 1 important warning sign

    Looking for more investment ideas beyond Demant?

    If Demant has sharpened your interest in hearing healthcare and valuation stories, do not stop here. Expand your watchlist with a few focused stock ideas.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.